-
Something wrong with this record ?
Aspartate-glutamate carrier 2 (citrin): a role in glucose and amino acid metabolism in the liver
M. Holeček
Language English Country Korea (South)
Document type News
NLK
Directory of Open Access Journals
from 2008
Free Medical Journals
from 2008
PubMed Central
from 2012 to 1 month ago
Europe PubMed Central
from 2012 to 1 month ago
Open Access Digital Library
from 2008-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2008
- MeSH
- Glucose * metabolism MeSH
- Liver metabolism MeSH
- Aspartic Acid * metabolism MeSH
- Glutamic Acid metabolism MeSH
- Publication type
- News MeSH
Aspartate-glutamate carrier 2 (AGC2, citrin) is a mitochondrial carrier expressed in the liver that transports aspartate from mitochondria into the cytosol in exchange for glutamate. The AGC2 is the main component of the malate-aspartate shuttle (MAS) that ensures indirect transport of NADH produced in the cytosol during glycolysis, lactate oxidation to pyruvate, and ethanol oxidation to acetaldehyde into mitochondria. Through MAS, AGC2 is necessary to maintain intracellular redox balance, mitochondrial respiration, and ATP synthesis. Through elevated cytosolic Ca2+ level, the AGC2 is stimulated by catecholamines and glucagon during starvation, exercise, and muscle wasting disorders. In these conditions, AGC2 increases aspartate input to the urea cycle, where aspartate is a source of one of two nitrogen atoms in the urea molecule (the other is ammonia), and a substrate for the synthesis of fumarate that is gradually converted to oxaloacetate, the starting substrate for gluconeogenesis. Furthermore, aspartate is a substrate for the synthesis of asparagine, nucleotides, and proteins. It is concluded that AGC2 plays a fundamental role in the compartmentalization of aspartate and glutamate metabolism and linkage of the reactions of MAS, glycolysis, gluconeogenesis, amino acid catabolism, urea cycle, protein synthesis, and cell proliferation. Targeting of AGC genes may represent a new therapeutic strategy to fight cancer. [BMB Reports 2023; 56(7): 385-391].
Department of Physiology Faculty of Medicine Charles University Hradec Králové 500 03 Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016982
- 003
- CZ-PrNML
- 005
- 20231026105349.0
- 007
- ta
- 008
- 231013s2023 ko f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5483/BMBRep.2023-0052 $2 doi
- 035 __
- $a (PubMed)37254569
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ko
- 100 1_
- $a Holeček, Milan $u Department of Physiology, Faculty of Medicine, Charles University, Hradec Králové 500 03, Czech Republic
- 245 10
- $a Aspartate-glutamate carrier 2 (citrin): a role in glucose and amino acid metabolism in the liver / $c M. Holeček
- 520 9_
- $a Aspartate-glutamate carrier 2 (AGC2, citrin) is a mitochondrial carrier expressed in the liver that transports aspartate from mitochondria into the cytosol in exchange for glutamate. The AGC2 is the main component of the malate-aspartate shuttle (MAS) that ensures indirect transport of NADH produced in the cytosol during glycolysis, lactate oxidation to pyruvate, and ethanol oxidation to acetaldehyde into mitochondria. Through MAS, AGC2 is necessary to maintain intracellular redox balance, mitochondrial respiration, and ATP synthesis. Through elevated cytosolic Ca2+ level, the AGC2 is stimulated by catecholamines and glucagon during starvation, exercise, and muscle wasting disorders. In these conditions, AGC2 increases aspartate input to the urea cycle, where aspartate is a source of one of two nitrogen atoms in the urea molecule (the other is ammonia), and a substrate for the synthesis of fumarate that is gradually converted to oxaloacetate, the starting substrate for gluconeogenesis. Furthermore, aspartate is a substrate for the synthesis of asparagine, nucleotides, and proteins. It is concluded that AGC2 plays a fundamental role in the compartmentalization of aspartate and glutamate metabolism and linkage of the reactions of MAS, glycolysis, gluconeogenesis, amino acid catabolism, urea cycle, protein synthesis, and cell proliferation. Targeting of AGC genes may represent a new therapeutic strategy to fight cancer. [BMB Reports 2023; 56(7): 385-391].
- 650 12
- $a glukosa $x metabolismus $7 D005947
- 650 12
- $a kyselina asparagová $x metabolismus $7 D001224
- 650 _2
- $a játra $x metabolismus $7 D008099
- 650 _2
- $a kyselina glutamová $x metabolismus $7 D018698
- 655 _2
- $a zprávy $7 D016433
- 773 0_
- $w MED00165986 $t BMB reports $x 1976-670X $g Roč. 56, č. 7 (2023), s. 385-391
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37254569 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105342 $b ABA008
- 999 __
- $a ok $b bmc $g 2000480 $s 1203344
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 56 $c 7 $d 385-391 $e - $i 1976-670X $m BMB Reports $n BMB Rep $x MED00165986
- LZP __
- $a Pubmed-20231013